PRESS RELEASES

Date Title View
Toggle Summary CMX157 shows potential to treat multi-drug-resistant HIV and improve the activity and toxicity profile of Tenofovir
CMX157 shows potential to treat multi-drug-resistant HIV and improve the activity and toxicity profile of Tenofovir RESEARCH TRIANGLE PARK, NC, July 28, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of
View HTML
Toggle Summary Chimerix appoints two new Vice Presidents to Clinical Management Team
Chimerix appoints two new Vice Presidents to Clinical Management Team RESEARCH TRIANGLE PARK, NC, July 21, 2010 Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that it has expanded its clinical management team with the appointment of
View HTML
Toggle Summary Chimerix initiates Phase 1 Study of CMX157
-New HIV Compound to Be Evaluated for Safety, Tolerability and Active Antiviral Drug Levels
View HTML
Toggle Summary Chimerix appoints Thomas Pitler, Ph.D., VP, Business Development
Chimerix appoints Thomas Pitler, Ph.D., VP, Business Development RESEARCH TRIANGLE PARK, NC, May 6, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Thomas A. Pitler, Ph.D., has joined the company as Vice President,
View HTML
Toggle Summary Chimerix names George Painter, PhD, Chairman of the Board & CSO; appoints Kenneth Moch, President & CEO
Chimerix names George Painter, PhD, Chairman of the Board & CSO; appoints Kenneth Moch, President & CEO RESEARCH TRIANGLE PARK, NC, May 4, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I.
View HTML
Toggle Summary Chimerix to Present at Future Leaders in the Biotech Industry Conference
Chimerix to Present at Future Leaders in the Biotech Industry Conference Research Triangle Park, NC, March 29, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I.
View HTML
Toggle Summary Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
- New Broad-Spectrum Antiviral Agent to Be Evaluated for Preventative and Therapeutic Activity
View HTML
Toggle Summary Chimerix CEO George Painter, Ph.D., to Speak at Institute of Medicine Workshop
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix to Present at Two Upcoming Investor Conferences
Chimerix to Present at Two Upcoming Investor Conferences Chimerix to Present at Two Upcoming Investor Conferences RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases,
View HTML